Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2023-03-17 00:00:00 ET · period of report 2023-03-15 · accession 0001519692-23-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-17 | 2023-03-15 | TARS | Greenstein Leonard M. | CFO | M - OptEx | — | +4,462 | 38.8K | +13% | — |
| DM | 2023-03-17 | 2023-03-16 | TARS | Greenstein Leonard M. | CFO | S - Sale+OE | $13.44 | -5,313 | 33.4K | -14% | -$71.4K |
| D | 2023-03-17 | 2023-03-15 | TARS | Greenstein Leonard M. | CFO | M - OptEx | $0.00 | -4,462 | 13.4K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-15 | M | A | 4,462 | — | 38,751 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") |
| 2 | Common | Common Stock | 2023-03-16 | S | D | 313 | $13.43 | 38,438 | D | — | — | |
| 3 | Common | Common Stock | 2023-03-16 | S | D | 5,000 | $13.44 | 33,438 | D | — | — | (F4) The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $13.28 to $13.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Derivative | Restricted Stock Units | 2023-03-15 | M | D | 4,462 | $0.00 | 13,388 | D | — · — to — | 4,462 Common Stock | (F5) Each RSU represents a contingent right to receive one share of the Company's common stock. (F6) RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service. |